University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Updates
Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients
Related Resources
ARV Profiles
ARV Charts & Tables
Opportunistic Infections

The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet formulations of these drugs.

Lamivudine (children aged 3 months to 16 years)
Oral solution:
8 mg/kg QD or 4 mg/kg BID; maximum 300 mg per day
Tablet formulation:
Wt 14 to <20 kg: 150 mg QD or 75 mg BID
Wt ≥20 to <25 kg: 225 mg QD, or 75 mg QAM + 150 mg QPM
Wt ≥25 kg: 300 mg QD or 150 mg BID (adult dosage)
Abacavir (children aged 3 months to 16 years)
Oral solution:
16 mg/kg QD or 8 mg/kg BID; maximum 600 mg per day
Tablet formulation:
Wt 14 to <20 kg: 300 mg QD or 150 mg BID
Wt ≥20 to <25 kg: 450 mg QD, or 150 mg QAM + 300 mg QPM
Wt ≥25 kg: 600 mg QD or 300 mg BID (adult dosage)

The updated prescribing information should soon be available on Drugs@FDA.